Barr, P. M., Owen, C., Robak, T., Tedeschi, A., Bairey, O., Burger, J. A., . . . Ghia, P. (2022). Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood advances, 6(11), 3440-3450. https://doi.org/10.1182/bloodadvances.2021006434
Chicago-Zitierstil (17. Ausg.)Barr, Paul M., et al. "Up to 8-year Follow-up from RESONATE-2: First-line Ibrutinib Treatment for Patients with Chronic Lymphocytic Leukemia." Blood Advances 6, no. 11 (2022): 3440-3450. https://doi.org/10.1182/bloodadvances.2021006434.
MLA-Zitierstil (9. Ausg.)Barr, Paul M., et al. "Up to 8-year Follow-up from RESONATE-2: First-line Ibrutinib Treatment for Patients with Chronic Lymphocytic Leukemia." Blood Advances, vol. 6, no. 11, 2022, pp. 3440-3450, https://doi.org/10.1182/bloodadvances.2021006434.